Stokes Family Office’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.64M | Buy |
38,221
+29,782
| +353% | +$2.06M | 0.28% | 75 |
|
|
2025
Q1 | $586K | Sell |
8,439
-38
| -0.4% | -$2.64K | 0.07% | 144 |
|
|
2024
Q4 | $729K | Buy |
8,477
+230
| +3% | +$19.8K | 0.08% | 132 |
|
|
2024
Q3 | $982K | Hold |
8,247
| – | – | 0.11% | 118 |
|
|
2024
Q2 | $1.18M | Buy |
8,247
+272
| +3% | +$38.8K | 0.14% | 109 |
|
|
2024
Q1 | $1.02M | Hold |
7,975
| – | – | 0.13% | 116 |
|
|
2023
Q4 | $825K | Sell |
7,975
-1,749
| -18% | -$181K | 0.11% | 118 |
|
|
2023
Q3 | $884K | Sell |
9,724
-136
| -1% | -$12.4K | 0.1% | 139 |
|
|
2023
Q2 | $798K | Buy |
9,860
+450
| +5% | +$36.4K | 0.09% | 141 |
|
|
2023
Q1 | $749K | Sell |
9,410
-768
| -8% | -$61.1K | 0.09% | 135 |
|
|
2022
Q4 | $689K | Buy |
10,178
+322
| +3% | +$21.8K | 0.09% | 133 |
|
|
2022
Q3 | $491K | Sell |
9,856
-276
| -3% | -$13.8K | 0.07% | 155 |
|
|
2022
Q2 | $565K | Buy |
10,132
+300
| +3% | +$16.7K | 0.08% | 151 |
|
|
2022
Q1 | $546K | Buy |
9,832
+370
| +4% | +$20.5K | 0.07% | 156 |
|
|
2021
Q4 | $530K | Buy |
9,462
+52
| +0.6% | +$2.91K | 0.07% | 154 |
|
|
2021
Q3 | $452K | Buy |
9,410
+254
| +3% | +$12.2K | 0.06% | 154 |
|
|
2021
Q2 | $384K | Buy |
9,156
+492
| +6% | +$20.6K | 0.05% | 158 |
|
|
2021
Q1 | $291K | Buy |
8,664
+922
| +12% | +$31K | 0.05% | 165 |
|
|
2020
Q4 | $270K | Hold |
7,742
| – | – | 0.05% | 144 |
|
|
2020
Q3 | $269K | Buy |
7,742
+742
| +11% | +$25.8K | 0.06% | 131 |
|
|
2020
Q2 | $229K | Sell |
7,000
-98
| -1% | -$3.21K | 0.06% | 119 |
|
|
2020
Q1 | $214K | Hold |
7,098
| – | – | 0.06% | 112 |
|
|
2019
Q4 | $205K | Buy |
+7,098
| New | +$205K | 0.05% | 122 |
|